Alicia B. Mitchell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alicia B. Mitchell has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Allan R. Glanville
The Lung Transplant Unit St. Vincent's Hospital Sydney Australia
7 shared publications- Brian Gregory Oliver
The Woolcock Institute of Medical Research, Macquarie University, Sydney, NSW 2113, Australia
6 shared publications - Allan R. Glanville
The Lung Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia
5 shared publications - Bassel Mourad
The Woolcock Institute of Medical Research, Sydney, New South Wales, Australia; School of Medical and Molecular Biosciences, University of Technology Sydney, Sydney, New South Wales, Australia
3 shared publications - Lucy Morgan
Department of Respiratory Medicine, Concord Clinical School, University of Sydney, Sydney, Australia
3 shared publications - Matthew J. Peters
Asbestos Dust Diseases Research Institute (ADDRI), Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2113, Australia
2 shared publications
Latest Publications
- Open Access
- 11 February 2025
- Published by Health Education and Training Institute - HETI in Health Education in Practice: Journal of Research for Professional Learning
- Vol. 8 (1)
Evaluating the impact of the Assistant in Medicine (AiM) program on medical workforce efficiency and preparedness in NSW, Australia
The Assistant in Medicine (AiM) program allows selected final-year medical students to take on more responsibility while also supporting the junior doctor workforce. This study aimed to evaluate the impact of the AiM program on current medical staff, including junior doctors, registrars and consultants working in public teaching hospitals on NSW’s Central Coast. Furthermore, it aimed to investigate the effect of this AiM program on final-year medical students, their learning and the transition to internship. This cross-sectional study surveyed a select group of 75 medical officers and all 28 final-year medical students employed as AiMs on the Central Coast during July– September 2023. Of the medical officers surveyed, 53.3% felt that they were able to see more, or substantially more, patients on a shift where they had an AiM present and 71.8% felt that a shift with an AiM present was more or substantially more enjoyable than one without. Our results also show that the AiM program allowed doctors to focus on higher-level tasks and to find more enjoyment in their shifts, which may be beneficial in reducing the high rates of burnout seen in the current junior doctor cohort. The entire cohort of student respondents indicated that the AiM position helped them to feel more prepared for internship, with 95% feeling more integrated into the team, indicating enhanced clinical readiness. Furthermore, this study indicates that all the final-year medical students participating in the AiM program on the Central Coast found the program to be beneficial to their learning, increasing their exposure to clinical skills and better preparing them for internship. Limitations of this study include a low response rate from doctors working in the local health district and the limited ability to explore qualitative data within the current study design.
- 11 February 2025
- Published by Health Education and Training Institute - HETI in Health Education in Practice: Journal of Research for Professional Learning
- Vol. 8 (1)
Open AccessEvaluating the impact of the Assistant in Medicine (AiM) program on medical workforce efficiency and preparedness in NSW, Australia
The Assistant in Medicine (AiM) program allows selected final-year medical students to take on more responsibility while also supporting the junior doctor workforce. This study aimed to evaluate the impact of the AiM program on current medical staff, including junior doctors, registrars and consultants working in public teaching hospitals on NSW’s Central Coast. Furthermore, it aimed to investigate the effect of this AiM program on final-year medical students, their learning and the transition to internship. This cross-sectional study surveyed a select group of 75 medical officers and all 28 final-year medical students employed as AiMs on the Central Coast during July– September 2023. Of the medical officers surveyed, 53.3% felt that they were able to see more, or substantially more, patients on a shift where they had an AiM present and 71.8% felt that a shift with an AiM present was more or substantially more enjoyable than one without. Our results also show that the AiM program allowed doctors to focus on higher-level tasks and to find more enjoyment in their shifts, which may be beneficial in reducing the high rates of burnout seen in the current junior doctor cohort. The entire cohort of student respondents indicated that the AiM position helped them to feel more prepared for internship, with 95% feeling more integrated into the team, indicating enhanced clinical readiness. Furthermore, this study indicates that all the final-year medical students participating in the AiM program on the Central Coast found the program to be beneficial to their learning, increasing their exposure to clinical skills and better preparing them for internship. Limitations of this study include a low response rate from doctors working in the local health district and the limited ability to explore qualitative data within the current study design.
- 7 September 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14142
The role of systemic steroids in lung transplant recipients with community‐acquired respiratory viruses: Time for a moratorium, or not?
- 7 September 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14142
The role of systemic steroids in lung transplant recipients with community‐acquired respiratory viruses: Time for a moratorium, or not?
- 25 January 2022
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 27 (3) , 217-221
The pulmonary microbiome: recent advances in understanding its role in chronic lung allograft dysfunction
Purpose of review: Lung transplantation presents a rescue therapy for those with end-stage lung disease. Survival in lung transplant patients remains limited due to chronic lung allograft dysfunction (CLAD), a range of pathologic manifestations leading to graft loss. The mechanisms underlying CLAD remain poorly understood, and the lung microbiome has been suggested as a potential contributor to this condition. This review aims to explore how the pulmonary microbiome is impacted by lung transplantation, and how alterations in this microbiome may contribute to the pathogenesis of CLAD. Recent findings: The pulmonary microbiome is made up of a range of microorganisms, and it varies considerably in lung transplant patients when compared with healthy controls. The lung microbiome changes over the early transplant period, and the composition of species appears to have an impact on inflammatory responses within the lungs. A number of studies have shown that an increase in bacterial biomass in the allograft, and enrichment with the genera Proteobacteria, or more specifically, Pseudomonas species, is associated with CLAD. Summary: This area of research is still in its infancy; however, the suggestion that changes in the composition of the microbiome and enrichment with certain species may predispose to the pathologic changes that underlie CLAD indicate that modulation of the microbiome may be of use in potential future therapeutics.
- 25 January 2022
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 27 (3) , 217-221
The pulmonary microbiome: recent advances in understanding its role in chronic lung allograft dysfunction
Purpose of review: Lung transplantation presents a rescue therapy for those with end-stage lung disease. Survival in lung transplant patients remains limited due to chronic lung allograft dysfunction (CLAD), a range of pathologic manifestations leading to graft loss. The mechanisms underlying CLAD remain poorly understood, and the lung microbiome has been suggested as a potential contributor to this condition. This review aims to explore how the pulmonary microbiome is impacted by lung transplantation, and how alterations in this microbiome may contribute to the pathogenesis of CLAD. Recent findings: The pulmonary microbiome is made up of a range of microorganisms, and it varies considerably in lung transplant patients when compared with healthy controls. The lung microbiome changes over the early transplant period, and the composition of species appears to have an impact on inflammatory responses within the lungs. A number of studies have shown that an increase in bacterial biomass in the allograft, and enrichment with the genera Proteobacteria, or more specifically, Pseudomonas species, is associated with CLAD. Summary: This area of research is still in its infancy; however, the suggestion that changes in the composition of the microbiome and enrichment with certain species may predispose to the pathologic changes that underlie CLAD indicate that modulation of the microbiome may be of use in potential future therapeutics.
- 24 May 2021
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 42 (03) , 436-448
The Impact of Resistant Bacterial Pathogens including Pseudomonas aeruginosa and Burkholderia on Lung Transplant Outcomes
Pseudomonas and Burkholderia are gram-negative organisms that achieve colonization within the lungs of patients with cystic fibrosis, and are associated with accelerated pulmonary function decline. Multidrug resistance is a hallmark of these organisms, which makes eradication efforts difficult. Furthermore, the literature has outlined increased morbidity and mortality for lung transplant (LTx) recipients infected with these bacterial genera. Indeed, many treatment centers have considered Burkholderia cepacia infection an absolute contraindication to LTx. Ongoing research has delineated different species within the B. cepacia complex (BCC), with significantly varied morbidity and survival profiles. This review considers the current evidence for LTx outcomes between the different subspecies encompassed within these genera as well as prophylactic and management options. The availability of meta-genomic tools will make differentiation between species within these groups easier in the future, and will allow more evidence-based decisions to be made regarding suitability of candidates colonized with these resistant bacteria for LTx. This review suggests that based on the current evidence, not all species of BCC should be considered contraindications to LTx, going forward. Publication Date: 24 May 2021 (online) © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 24 May 2021
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 42 (03) , 436-448
The Impact of Resistant Bacterial Pathogens including Pseudomonas aeruginosa and Burkholderia on Lung Transplant Outcomes
Pseudomonas and Burkholderia are gram-negative organisms that achieve colonization within the lungs of patients with cystic fibrosis, and are associated with accelerated pulmonary function decline. Multidrug resistance is a hallmark of these organisms, which makes eradication efforts difficult. Furthermore, the literature has outlined increased morbidity and mortality for lung transplant (LTx) recipients infected with these bacterial genera. Indeed, many treatment centers have considered Burkholderia cepacia infection an absolute contraindication to LTx. Ongoing research has delineated different species within the B. cepacia complex (BCC), with significantly varied morbidity and survival profiles. This review considers the current evidence for LTx outcomes between the different subspecies encompassed within these genera as well as prophylactic and management options. The availability of meta-genomic tools will make differentiation between species within these groups easier in the future, and will allow more evidence-based decisions to be made regarding suitability of candidates colonized with these resistant bacteria for LTx. This review suggests that based on the current evidence, not all species of BCC should be considered contraindications to LTx, going forward. Publication Date: 24 May 2021 (online) © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 22 February 2021
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (12) , 2546-2553
High-resolution Metatranscriptomic Characterization of the Pulmonary RNA Virome After Lung Transplantation
Background: Lung transplantation provides a unique opportunity to investigate the constituents and temporal dynamics of the human pulmonary microbiome after lung transplantation. For methodological reasons, prior studies using metagenomics have detected DNA viruses but not demonstrated the presence of RNA viruses, including those that are common community acquired. In this proof-of-concept study, we aimed to further characterize the pulmonary microbiome after lung transplantation by using metagenomic next-generation sequencing (mNGS), with a particular focus on the RNA virome. Methods: We performed a single-center longitudinal study of lower respiratory tract RNA viruses and bacteria using bronchoalveolar lavage at postoperative day 1 and week 6 analyzed with total RNA sequencing (metatranscriptomics). Five primary and 5 repeat transplant recipients were recruited. Results: mNGS identified 5 RNA viruses (nil in the normal saline control), including 4 species of human rhinovirus not previously reported in Australia: A7 (HRV-A7), C22 (HRV-C22), B52 (HRV-B52) and B72 (HRV-B72). Overall, 12/20 specimens were virus positive in 7/10 cases. Human parainfluenza virus 3 was the most frequent virus in 7/20 specimens in 5/10 cases. In this small study we did not detect a significant difference in abundance and diversity of RNA viruses and bacteria at postoperative day 1 and 6 weeks, nor differences between retransplant recipients and primary lung transplant recipients. Conclusions: Our study demonstrates how mNGS can also identify RNA viruses within the human pulmonary virome, including novel RNA viruses, and paves the way for a greater understanding of the complex relationships among the constituents of the pulmonary infectome. SUPPLEMENTAL DIGITAL CONTENT: This article has an online data supplement which is accessible http://links.lww.com/TP/C156
- 22 February 2021
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (12) , 2546-2553
High-resolution Metatranscriptomic Characterization of the Pulmonary RNA Virome After Lung Transplantation
Background: Lung transplantation provides a unique opportunity to investigate the constituents and temporal dynamics of the human pulmonary microbiome after lung transplantation. For methodological reasons, prior studies using metagenomics have detected DNA viruses but not demonstrated the presence of RNA viruses, including those that are common community acquired. In this proof-of-concept study, we aimed to further characterize the pulmonary microbiome after lung transplantation by using metagenomic next-generation sequencing (mNGS), with a particular focus on the RNA virome. Methods: We performed a single-center longitudinal study of lower respiratory tract RNA viruses and bacteria using bronchoalveolar lavage at postoperative day 1 and week 6 analyzed with total RNA sequencing (metatranscriptomics). Five primary and 5 repeat transplant recipients were recruited. Results: mNGS identified 5 RNA viruses (nil in the normal saline control), including 4 species of human rhinovirus not previously reported in Australia: A7 (HRV-A7), C22 (HRV-C22), B52 (HRV-B52) and B72 (HRV-B72). Overall, 12/20 specimens were virus positive in 7/10 cases. Human parainfluenza virus 3 was the most frequent virus in 7/20 specimens in 5/10 cases. In this small study we did not detect a significant difference in abundance and diversity of RNA viruses and bacteria at postoperative day 1 and 6 weeks, nor differences between retransplant recipients and primary lung transplant recipients. Conclusions: Our study demonstrates how mNGS can also identify RNA viruses within the human pulmonary virome, including novel RNA viruses, and paves the way for a greater understanding of the complex relationships among the constituents of the pulmonary infectome. SUPPLEMENTAL DIGITAL CONTENT: This article has an online data supplement which is accessible http://links.lww.com/TP/C156
- 1 March 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 104 (3) , 450-451
Antibiotic Pretreatment for Liver Transplantation: A Game Changer?
- 1 March 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 104 (3) , 450-451
Antibiotic Pretreatment for Liver Transplantation: A Game Changer?
- 1 June 2019
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (3) , 305-310
The lung microbiome and transplantation
Purpose of review: Lung transplantation survival is still limited compared with other solid organ transplant modalities, due to a range of factors that are continuing to be elucidated. However, new research is emerging which indicates that the microbiome of the lungs, and of other organs, may have important implications for immune response and mediating transplant outcomes. Pathogenic bacterial and viral species are known to have deleterious effects on the allograft, but taking a more global view, and considering the overall composition of the community of microbial species may undercover a greater understanding of the complex interplay involved in allograft dysfunction. Recent findings: The microbiome appears to have an important modulatory role on immune response in both normal development, and after transplantation. A range of microbial species contributes to the resident microscopic community, with the gut and blood microbiomes having a significant impact on the function of the lungs and resistance to infection. Movement of species from within and outside the respiratory tract occurs in the early transplant period, leading to a modified donor microbiome in the recipient. There is evidence to suggest that chronic lung allograft dysfunction may be facilitated by the respiratory microbiome and interactions with immune cells within the allograft. Summary: Further investigation of the respiratory microbiome, interactions with the microbiome of other organs and impact on immune and allograft function posttransplantation is needed. Promising insights are being gained regarding certain microbial profiles which may be associated with negative outcomes, and the mechanisms through which this occurs. As our understanding expands, the ability to modify the microbiome offers novel treatment strategies for combating allograft dysfunction.
- 1 June 2019
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (3) , 305-310
The lung microbiome and transplantation
Purpose of review: Lung transplantation survival is still limited compared with other solid organ transplant modalities, due to a range of factors that are continuing to be elucidated. However, new research is emerging which indicates that the microbiome of the lungs, and of other organs, may have important implications for immune response and mediating transplant outcomes. Pathogenic bacterial and viral species are known to have deleterious effects on the allograft, but taking a more global view, and considering the overall composition of the community of microbial species may undercover a greater understanding of the complex interplay involved in allograft dysfunction. Recent findings: The microbiome appears to have an important modulatory role on immune response in both normal development, and after transplantation. A range of microbial species contributes to the resident microscopic community, with the gut and blood microbiomes having a significant impact on the function of the lungs and resistance to infection. Movement of species from within and outside the respiratory tract occurs in the early transplant period, leading to a modified donor microbiome in the recipient. There is evidence to suggest that chronic lung allograft dysfunction may be facilitated by the respiratory microbiome and interactions with immune cells within the allograft. Summary: Further investigation of the respiratory microbiome, interactions with the microbiome of other organs and impact on immune and allograft function posttransplantation is needed. Promising insights are being gained regarding certain microbial profiles which may be associated with negative outcomes, and the mechanisms through which this occurs. As our understanding expands, the ability to modify the microbiome offers novel treatment strategies for combating allograft dysfunction.
- 1 April 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (4) , 660-661
Kinetics of TTV-DNA Plasma Load: A Global Measure of Immune Suppression?
Torque teno viruses (TTV) have received attention in recent studies that have examined their presence and dynamics in the general population, and particularly after transplantation.1 The overall consensus is that TTV are nonpathogenic, resident members of the human virome which have been shown to be ubiquitous in the blood of healthy individuals.1 A range of studies has demonstrated divergent levels of TTV in different diseases and has suggested that TTV levels may correlate with levels of immunosuppression and immune response.2 As successful solid organ transplantation relies on a balance between these 2 factors, TTV load monitoring as a surrogate for effective immunosuppression is a promising avenue for research. The ambient and optimum level of immune suppression likely varies between individuals and within the 1 individual at different time points after transplantation. Therapeutic drug monitoring is 1 tool to measure the levels of immune suppressive drugs achieved but has a poor relationship with overall burden of immune suppression partly due to the imprecision of single point surrogate measures when compared to area under the drug concentration curve monitoring.3 This is particularly relevant after lung transplantation where 1 target group is the cystic fibrosis population where absorption and metabolism are demonstrably different from the non–cystic fibrosis population.4,5 At divergent ends of the spectrum of immune suppression are the risks of opportunistic infection and rejection, including both acute cellular rejection (ACR) and antibody-mediated rejection.6 Both may contribute to adverse outcomes in the pulmonary allograft, specifically, as risk factors for chronic rejection, manifest as bronchiolitis obliterans syndrome, or restrictive allograft syndrome, both of which phenotypes fall under the umbrella term of chronic lung allograft dysfunction.7,8 The current single-center retrospective study by Frye et al,9 correlated kinetics of TTV-DNA plasma load with outcomes after lung transplantation and found reductions in load were predictive of the development of ACR. Patients with infections had higher TTV-DNA plasma loads from day 180 onward. Results presented are at variance with prior studies from Vienna, 1 explanation for which is the use of different protocols for TTV-DNA plasma load measurement.10 Quantitative polymerase chain reaction (PCR) for determining the load, or absolute amount of TTV virus within a sample, depends on a number of factors, which may explain the discrepancy in TTV levels found between the 2 studies.10 However, the retrospective nature of this study means that collected samples may not have been optimized for viral analysis with uniform processing and storage. Prospective analyses on recently collected and careful stored samples may yield slightly different results and as mentioned, utilization of the same PCR primers for TTV, across studies, may be important due to the large amount of genetic variation exhibited by this virus.11 As the authors state, therapeutic drug monitoring of immunosuppression was not correlated with TTV-DNA plasma load. Although there was a higher TTV-DNA plasma load in patients with infections, this cannot be implied directly to show a greater burden of immunosuppression. One plausible explanation for the apparent lack of association between TTV-DNA plasma load and immunosuppression levels is that calcineurin inhibitor trough levels may not be an accurate guide to total calcineurin inhibitor exposure. Also, the global burden of immunosuppression (including the cell cycle inhibiters and corticosteroids, especially pulse corticosteroid therapy) needs to be considered. In the cohort studied, TTV-DNA plasma load monitoring was more informative than drug trough level monitoring, which perhaps bespeaks the error signal in single point surrogates of area under the drug concentration curve.
- 1 April 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (4) , 660-661
Kinetics of TTV-DNA Plasma Load: A Global Measure of Immune Suppression?
Torque teno viruses (TTV) have received attention in recent studies that have examined their presence and dynamics in the general population, and particularly after transplantation.1 The overall consensus is that TTV are nonpathogenic, resident members of the human virome which have been shown to be ubiquitous in the blood of healthy individuals.1 A range of studies has demonstrated divergent levels of TTV in different diseases and has suggested that TTV levels may correlate with levels of immunosuppression and immune response.2 As successful solid organ transplantation relies on a balance between these 2 factors, TTV load monitoring as a surrogate for effective immunosuppression is a promising avenue for research. The ambient and optimum level of immune suppression likely varies between individuals and within the 1 individual at different time points after transplantation. Therapeutic drug monitoring is 1 tool to measure the levels of immune suppressive drugs achieved but has a poor relationship with overall burden of immune suppression partly due to the imprecision of single point surrogate measures when compared to area under the drug concentration curve monitoring.3 This is particularly relevant after lung transplantation where 1 target group is the cystic fibrosis population where absorption and metabolism are demonstrably different from the non–cystic fibrosis population.4,5 At divergent ends of the spectrum of immune suppression are the risks of opportunistic infection and rejection, including both acute cellular rejection (ACR) and antibody-mediated rejection.6 Both may contribute to adverse outcomes in the pulmonary allograft, specifically, as risk factors for chronic rejection, manifest as bronchiolitis obliterans syndrome, or restrictive allograft syndrome, both of which phenotypes fall under the umbrella term of chronic lung allograft dysfunction.7,8 The current single-center retrospective study by Frye et al,9 correlated kinetics of TTV-DNA plasma load with outcomes after lung transplantation and found reductions in load were predictive of the development of ACR. Patients with infections had higher TTV-DNA plasma loads from day 180 onward. Results presented are at variance with prior studies from Vienna, 1 explanation for which is the use of different protocols for TTV-DNA plasma load measurement.10 Quantitative polymerase chain reaction (PCR) for determining the load, or absolute amount of TTV virus within a sample, depends on a number of factors, which may explain the discrepancy in TTV levels found between the 2 studies.10 However, the retrospective nature of this study means that collected samples may not have been optimized for viral analysis with uniform processing and storage. Prospective analyses on recently collected and careful stored samples may yield slightly different results and as mentioned, utilization of the same PCR primers for TTV, across studies, may be important due to the large amount of genetic variation exhibited by this virus.11 As the authors state, therapeutic drug monitoring of immunosuppression was not correlated with TTV-DNA plasma load. Although there was a higher TTV-DNA plasma load in patients with infections, this cannot be implied directly to show a greater burden of immunosuppression. One plausible explanation for the apparent lack of association between TTV-DNA plasma load and immunosuppression levels is that calcineurin inhibitor trough levels may not be an accurate guide to total calcineurin inhibitor exposure. Also, the global burden of immunosuppression (including the cell cycle inhibiters and corticosteroids, especially pulse corticosteroid therapy) needs to be considered. In the cohort studied, TTV-DNA plasma load monitoring was more informative than drug trough level monitoring, which perhaps bespeaks the error signal in single point surrogates of area under the drug concentration curve.
- Open Access
- 1 January 2019
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 5 (1) , e416
Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission
In 2016, the Transplantation Society of Australia and New Zealand, with the support of the Australian Government Organ and Tissue authority, commissioned a literature review on the topic of infectious disease transmission from deceased donors to recipients of solid organ transplants. The purpose of this review was to synthesize evidence on transmission risks, diagnostic test characteristics, and recipient management to inform best-practice clinical guidelines. The final review, presented as a special supplement in Transplantation Direct, collates case reports of transmission events and other peer-reviewed literature, and summarizes current (as of June 2017) international guidelines on donor screening and recipient management. Of particular interest at the time of writing was how to maximize utilization of donors at increased risk for transmission of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, given the recent developments, including the availability of direct-acting antivirals for hepatitis C virus and improvements in donor screening technologies. The review also covers emerging risks associated with recent epidemics (eg, Zika virus) and the risk of transmission of nonendemic pathogens related to donor travel history or country of origin. Lastly, the implications for recipient consent of expanded utilization of donors at increased risk of blood-borne viral disease transmission are considered.
- 1 January 2019
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 5 (1) , e416
Open AccessInfectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission
In 2016, the Transplantation Society of Australia and New Zealand, with the support of the Australian Government Organ and Tissue authority, commissioned a literature review on the topic of infectious disease transmission from deceased donors to recipients of solid organ transplants. The purpose of this review was to synthesize evidence on transmission risks, diagnostic test characteristics, and recipient management to inform best-practice clinical guidelines. The final review, presented as a special supplement in Transplantation Direct, collates case reports of transmission events and other peer-reviewed literature, and summarizes current (as of June 2017) international guidelines on donor screening and recipient management. Of particular interest at the time of writing was how to maximize utilization of donors at increased risk for transmission of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, given the recent developments, including the availability of direct-acting antivirals for hepatitis C virus and improvements in donor screening technologies. The review also covers emerging risks associated with recent epidemics (eg, Zika virus) and the risk of transmission of nonendemic pathogens related to donor travel history or country of origin. Lastly, the implications for recipient consent of expanded utilization of donors at increased risk of blood-borne viral disease transmission are considered.